Nursing Elites

1. What should you monitor when administering Clopidogrel to a patient?

• A. Signs of thrombotic thrombocytopenic purpura
• B. Bleeding during therapy
• C. CBC with differential and platelet count
• D. All of the above

Correct answer: D

Rationale: When administering Clopidogrel, it is crucial to monitor for signs of thrombotic thrombocytopenic purpura, bleeding during therapy, and changes in CBC with differential and platelet count. Thrombotic thrombocytopenic purpura is a rare but serious condition associated with Clopidogrel use, characterized by microangiopathic hemolytic anemia, thrombocytopenia, neurological symptoms, fever, and renal dysfunction. Monitoring for signs of thrombotic thrombocytopenic purpura is essential to detect this potentially life-threatening condition early. Monitoring for bleeding helps to assess the risk of hemorrhagic events, a known side effect of Clopidogrel. Additionally, regular monitoring of CBC with differential and platelet count is necessary to evaluate the drug's impact on blood cell counts and detect any abnormalities that may require intervention. Therefore, monitoring all these parameters is vital to ensure patient safety and appropriate management during Clopidogrel therapy.

2. A healthcare professional is caring for a client who is receiving heparin therapy. Which of the following laboratory tests should the healthcare professional monitor to evaluate the therapeutic effect of heparin?

• A. PT/INR
• B. Platelet count
• C. aPTT
• D. WBC count

Correct answer: C

Rationale: The correct test to monitor the therapeutic effect of heparin is the activated partial thromboplastin time (aPTT). Heparin's action is to prolong the clotting time, and aPTT reflects this effect. Monitoring aPTT helps ensure that the client is within the therapeutic range to prevent clot formation while minimizing the risk of bleeding complications. PT/INR is used to monitor warfarin therapy, platelet count assesses for potential thrombocytopenia, and WBC count evaluates for signs of infection or inflammation, not the therapeutic effect of heparin.

3. A healthcare provider is educating a client who has a new prescription for Simvastatin. Which of the following instructions should the healthcare provider include?

• A. Take this medication with food.
• B. Avoid drinking grapefruit juice.
• C. Take this medication in the morning.
• D. Increase your intake of potassium-rich foods.

Correct answer: B

Rationale: The correct instruction that the healthcare provider should include is to 'Avoid drinking grapefruit juice.' Grapefruit juice can increase the blood levels of Simvastatin, leading to potential side effects like muscle pain and liver damage. Instructing the client to avoid grapefruit juice helps prevent these adverse effects and ensures the medication's efficacy. Choices A, C, and D are incorrect because taking Simvastatin with food, at a specific time, or increasing potassium-rich foods intake are not essential instructions for this medication.

4. A client has been prescribed a Beta Blocker for hypertension. Which of the following findings should the nurse monitor as an adverse effect of this medication?

• A. Bradycardia
• B. Hypertension
• C. Hyperglycemia
• D. Hypernatremia

Correct answer: A

Rationale: Bradycardia is the correct answer. Beta Blockers work by slowing down the heart rate, which can lead to bradycardia as an adverse effect. Monitoring for bradycardia is essential to prevent complications. Choices B, C, and D are incorrect because Beta Blockers do not typically cause hypertension, hyperglycemia, or hypernatremia as adverse effects.

5. Which of the following is a potassium-sparing diuretic?

• A. Furosemide
• B. Spironolactone
• C. Hydrochlorothiazide
• D. Bumetanide

Correct answer: B

Rationale: Spironolactone is classified as a potassium-sparing diuretic. It works by antagonizing the aldosterone receptor, leading to potassium retention and sodium excretion. This mechanism makes it a suitable choice for conditions where potassium retention is desired, such as in patients with heart failure or liver cirrhosis. Choices A, C, and D are not potassium-sparing diuretics. Furosemide, hydrochlorothiazide, and bumetanide are loop diuretics and thiazide diuretics, respectively, which promote the excretion of potassium.

Similar Questions